Somu is the Managing Partner and co-founder of New Science Ventures. Somu serves on the Board of Directors of Alexar Therapeutics, Achronix Semiconductor Corporation, Vascular Therapies, Dali Wireless, Cambridge Epigenetics, Oxyrane, Resolve Therapeutics, Svelte Medical Systems and iCAD. Somu has previously served on the Boards of Dezima Pharma (sold to Amgen), Ception (sold to Cephalon), BioVex (sold to Amgen), Lightwire (sold to Cisco) and K2M (sold to Welsh Carson). Prior to founding NSV, Somu was a Director of McKinsey & Co. and at various times led their Strategy practice, Technology practice and HealthCare practice. He was also a member of McKinsey’s Investment Committee. Somu received his undergraduate degree (B.Tech.) from the Indian Institute of Technology and his M.B.A. from Harvard Business School.